Considerations for Amphotericin B Use in Heart Failure Patients

Preferred Formulations and Administration

The American College of Cardiology and other guideline societies recommend using lipid formulations of amphotericin B instead of conventional amphotericin B deoxycholate in patients with heart failure due to lower cardiovascular risk 1, 2
Liposomal amphotericin B is particularly recommended for its better cardiovascular safety profile, reduced nephrotoxicity, and lower incidence of infusion-related reactions 2, 3
Administer lipid formulations over at least 2 hours to prevent hypotension and arrhythmias 4

Regular assessment of renal function is essential as nephrotoxicity can worsen heart failure, with more frequent monitoring in patients with pre-existing renal dysfunction 1
Baseline and frequent cardiac assessment, including ECG monitoring before and during treatment, is crucial 4
Preventive measures such as sodium loading, volume repletion, potassium and magnesium supplementation, and discontinuation of diuretics can help reduce cardiovascular risk 1

For fungal endocarditis in patients with heart failure, early consultation with infectious disease, cardiology, and cardiac surgery services is essential, and surgical intervention in conjunction with antifungal therapy is often required 3, 6
Liposomal forms of amphotericin B are preferred for native valve fungal endocarditis in patients with heart failure 3, 6
For histoplasmosis treatment in heart failure patients, lipid formulation of amphotericin B is recommended for severe disease, with liposomal amphotericin B demonstrating higher response rates and lower mortality compared to conventional formulations 7